Emergent BioSolutions (EBS) CFO logs 683-share tax-withholding disposition

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported a routine insider equity transaction by its EVP and Chief Financial Officer, Richard S. Lindahl. On the reported date, 683 shares of common stock were disposed of at $8.15 per share to cover tax withholding tied to the vesting and settlement of restricted stock units. After this tax-withholding disposition, Lindahl directly owned 239,017 shares of Emergent BioSolutions common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026	03/02/2026	F		683(1)	D	$8.15	239,017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Richard S. Lindahl	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Emergent BioSolutions (EBS) report in this Form 4?

Emergent BioSolutions reported that EVP and CFO Richard S. Lindahl had 683 shares of common stock withheld to pay taxes tied to restricted stock unit vesting, priced at $8.15 per share, leaving him with 239,017 directly owned shares.

Who is the insider involved in the latest Emergent BioSolutions (EBS) Form 4?

The insider is Richard S. Lindahl, Executive Vice President and Chief Financial Officer. He reported a tax-related share disposition of 683 common shares, linked to restricted stock unit vesting, and now directly holds 239,017 Emergent BioSolutions common shares.

How many Emergent BioSolutions (EBS) shares were disposed of for tax withholding?

A total of 683 Emergent BioSolutions common shares were disposed of to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units, at a reported price of $8.15 per share, according to the Form 4.

Did the Emergent BioSolutions (EBS) CFO sell shares on the open market?

No, the transaction was a tax-withholding disposition, not an open-market sale. Shares were withheld to pay taxes due on restricted stock unit vesting, as described in the Form 4 footnote for Richard S. Lindahl.

How many Emergent BioSolutions (EBS) shares does the CFO own after this transaction?

After the tax-withholding disposition of 683 shares, Executive Vice President and Chief Financial Officer Richard S. Lindahl directly owns 239,017 shares of Emergent BioSolutions common stock, according to the reported Form 4 ownership figures.

What does the F transaction code mean in the Emergent BioSolutions (EBS) Form 4?

The F transaction code indicates payment of a tax liability or exercise price by delivering securities. Here, it reflects shares withheld to pay taxes related to the vesting and settlement of restricted stock units for the Emergent BioSolutions CFO.